Louisiana State Employees Retirement System Purchases New Shares in Labcorp Holdings Inc. $LH

Louisiana State Employees Retirement System acquired a new stake in Labcorp Holdings Inc. (NYSE:LH) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 4,200 shares of the medical research company’s stock, valued at approximately $1,121,000.

Other large investors have also recently added to or reduced their stakes in the company. JPL Wealth Management LLC acquired a new stake in shares of Labcorp during the third quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Labcorp in the fourth quarter valued at about $26,000. Hilton Head Capital Partners LLC bought a new position in Labcorp during the fourth quarter worth about $27,000. Eagle Bay Advisors LLC bought a new position in Labcorp during the fourth quarter worth about $29,000. Finally, DV Equities LLC acquired a new stake in Labcorp in the 4th quarter worth about $29,000. Institutional investors own 95.94% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Adam H. Schechter sold 5,903 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the sale, the chief executive officer directly owned 107,234 shares of the company’s stock, valued at $27,291,053. This trade represents a 5.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn W. Kyle sold 762 shares of Labcorp stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $263.89, for a total value of $201,084.18. Following the completion of the transaction, the executive vice president owned 3,813 shares in the company, valued at approximately $1,006,212.57. This represents a 16.66% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.84% of the stock is currently owned by insiders.

Labcorp Stock Performance

Shares of Labcorp stock opened at $286.69 on Friday. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. The company has a market cap of $23.51 billion, a PE ratio of 25.39, a price-to-earnings-growth ratio of 2.01 and a beta of 0.89. The company has a 50 day moving average of $262.24 and a 200-day moving average of $266.25. Labcorp Holdings Inc. has a 1-year low of $241.81 and a 1-year high of $293.72.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The business had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.51 billion. During the same period last year, the firm posted $3.84 earnings per share. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, equities research analysts forecast that Labcorp Holdings Inc. will post 18 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Friday, May 29th were paid a $0.72 dividend. The ex-dividend date was Friday, May 29th. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. Labcorp’s dividend payout ratio (DPR) is presently 25.51%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Evercore reissued an “outperform” rating and issued a $300.00 price objective on shares of Labcorp in a report on Wednesday, April 8th. Robert W. Baird set a $334.00 target price on shares of Labcorp in a report on Friday, May 1st. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a research report on Friday, May 8th. Finally, Wall Street Zen cut Labcorp from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Labcorp presently has an average rating of “Moderate Buy” and an average target price of $308.00.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.